How a pharmaceutical giant balances massive innovation with aggressive legal and tax strategies

How a pharmaceutical giant balances massive innovation with aggressive legal and tax strategies
Image: Intellect (generated)

In short: AbbVie, a global pharmaceutical powerhouse, commands a massive portfolio of life-altering treatments, from Humira to Botox. Yet, its rise is marked by a complex web of high-stakes acquisitions, intense patent litigation, and scrutiny over its tax practices, illustrating the precarious tension between medical advancement and corporate profit-seeking.

Formed in 2012 as a spin-off from Abbott Laboratories, AbbVie has rapidly ascended to become a major player in the biomedical industry. The company’s growth strategy relies heavily on aggressive acquisitions, such as the $63 billion purchase of Allergan in 2019 and the $10.1 billion acquisition of ImmunoGen in 2024. These deals are designed to bolster its pipeline in oncology, immunology, and neuroscience, areas where the company maintains significant market presence through flagship products like Skyrizi and Rinvoq.

However, this expansion is frequently shadowed by controversy. AbbVie has faced sustained criticism for its use of 'patent thickets'—a strategy designed to extend market monopolies and delay the entry of cheaper biosimilars. A report from the House Oversight and Reform Committee accused the firm of exploiting the patent system and orphan drug protections to maintain high prices. Furthermore, the company has navigated significant legal challenges, including a $2.37 billion settlement regarding the marketing of opioid analgesics by its Allergan unit and various lawsuits alleging kickback schemes.

The company’s financial structure has also drawn legislative attention. A 2022 Senate Finance Committee report revealed that AbbVie utilized offshore intellectual property registration in jurisdictions like Bermuda to minimize its U.S. tax liability, despite the vast majority of its Humira sales occurring domestically. While the company continues to strike massive partnerships and invest in future therapies, it remains a focal point for debates regarding drug pricing, corporate tax ethics, and the balance of power between pharmaceutical giants and public health systems.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

  • Summary by Intellect · source: AbbVie

To cite this card, link to https://intellectplus.co.uk/app/wealth-abbvie.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…